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Abstract: The Wilms tumor 1 (WT1) gene has a complex role as a transcriptional regulator, acting as 
tumor suppressor or oncogene in different malignancies. The prognostic role of its overexpression has 
been well-studied in leukemias, especially acute myeloid leukemia (AML), but not in lymphomas. For the 
first time to our knowledge, we present a study demonstrating the correlation of WT1 expression and 
survival in various non-Hodgkin lymphomas. We also studied the prognostic implications of WT1 
overexpression in adult acute lymphoblastic leukemia (ALL). In our sample of 53 patients – 25 with 
diffuse large B-cell lymphoma (DLBCL), 8 with mantle cell lymphoma (MCL), 9 with peripheral T-cell 
lymphoma (PTCL), 2 with Burkitt’s lymphoma, 2 with mucosa-associated lymphoid tissue (MALT) 
lymphoma, and 7 with B-cell ALL –, we measured WT1 mRNA from blood samples by quantitative RT-
PCR, and divided the patients into subgroups based on the level of expression. Kaplan-Meier survival 
curves were drawn and compared using the logrank test. In the sample of DLBCL patients, the difference 
in overall and disease-free survival between WT1-positive and negative subgroups was significant 
(p=0,0475 and p=0,0004, respectively), and in a few observed cases, a sudden increase in WT1 
expression signified a relapse soon followed by death. Disease-free survival curves in MCL and ALL 
were similarly suggestive of a potential role played by WT1. In PTCL, though WT1-positivity was 
detected in 4 out of 9 cases, it did not seem to affect survival. The few cases of MALT and Burkitt’s 
lymphoma all proved to be WT1-negative. 
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Introduction 
 
The Wilms tumor 1 (WT1) gene is located at chromosomal region 11p13. It encodes a DNA-binding 
protein with 4 zinc finger domains, which has long been known to act as a tumor suppressor in Wilms 
tumor [1]. In other neoplasms, however, WT1 seems to play the opposite role as an oncogene. This may 
be due to a two-sided function of WT1 promoting differentiation of cells in the genitourinary tract, while 
maintaining an immature mesenchymal state in other tissues [2]. Complexity of the protein’s function is 
mainly attributed to the large number of isoforms: the first 4 were characterized in 1991 [3], but other 
variants were soon discovered, reaching a total of 24 identified isoproteins by the late 90s – and the 
theoretical limit of possible isoforms has only grown since then, as further data accumulated [4]. Still, the 
2 isoforms either including or excluding a tripeptide (KTS) due to the alternative splicing of exon 9 seem 
to be the most important from a practical aspect [5]. Apart from DNA-binding, WT1 might have a 
regulatory role at the posttranscriptional level as well [6]. 
 
Reports on high levels of WT1 expression in acute leukemias were published only 2 years after the gene’s 
discovery [7], and WT1-positive AML cases were associated with a bad prognosis [8]. Recently, WT1 
siRNA was used in the treatment of leukemic cell lines with some success [9], but the oncogenic role of 
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WT1 in hematological malignancies remains poorly understood. Besides the assessment of prognosis at 
diagnosis, measuring WT1 expression is also considered suitable for monitoring minimal residual disease 
in AML [10,11]. 
 
WT1 expression has been extensively studied in AML and myelodysplastic syndrome (MDS). In recent 
years, some results have been reported in childhood and adult ALL as well. These suggest that while 
WT1 expression is not a reliable marker of prognosis and minimal residual disease in ALL, WT1 could 
still become a therapeutic target, as its overexpression was detected in a sufficiently high number of cases 
[12-14]. For the majority of lymphomas, however, no studies have been published to report the possible 
prognostic significance of WT1 expression, even though a putative role of WT1 in their pathogenesis has 
been suggested, much like in acute leukemias [15]. 
  
Here, we studied WT1 expression in patients with different non-Hodgkin lymphomas and ALL, and 
examined the correlation between detected expression levels and clinical outcome. 
 
Materials and Methods 
 
53 patients were studied between March 2007 and May 2012: 25 with DLBCL, 8 with MCL, 9 with 
PTCL, 2 with Burkitt’s lymphoma, 2 with MALT lymphoma, and 7 with B-cell ALL. Morphological and 
immunophenotypic (by flow cytometry) classification was used to confirm cases of ALL, while in non-
Hodgkin lymphomas, a surgical lymph node excision or biopsy was used as a tissue source for 
pathological diagnosis, and the Ann Arbor system was applied for clinical staging. We took blood 
samples (multiple times in most cases: at diagnosis, during and after treatment) until the end of the study, 
last follow-up, or death of the patient. Written informed consent was obtained from all patients in 
accordance with the Declaration of Helsinki. 
 
Samples were collected in PAXgene Blood RNA Tubes, and stored at -20 °C. We used PAXgene Blood 
RNA Kits to extract RNA, and after reverse transcription by High Capacity cDNA Reverse Transcription 
Kits (Applied Biosystems), we detected cDNA levels using an Applied Biosystems 7500 Real Time PCR 
System with primers and a fluorescent Taqman probe specific to WT1 (commercial kit No. 
Hs00240913_m1) and a reference gene showing high and relatively constant expression (GAPDH). The 
housekeeping gene GAPDH is still favored as endogenous control in the literature, since its expression 
shows no difference in normal and neoplastic lymphoid tissue [16]. Rather than calculating with Ct values, 
we normalized WT1 expression against GAPDH, and used the resulting value (number of WT1 mRNA 
molecules per 10
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 GAPDH mRNA molecules) for further calculations. This method eliminated the 
problem of RNA extraction with varying degrees of efficiency from different samples, as we produced 
reliable results at low RNA concentrations, even below 1 ng/μL in a few cases (most of our RNA samples 
were in the 200-500 ng/μL range). 
 
We performed statistical analysis on calculated WT1 expression values using the software MedCalc 
(version 12.3.0).  Overall survival was calculated from the date of diagnosis until death or last follow-up. 
(Some of the patients were diagnosed earlier, and had been under treatment for years when they entered 
our study.) Disease-free survival was defined as the time spent in remission until relapse, death or last 
follow-up. Figures in our paper were also drawn by MedCalc. 
 
Controls 
 
Our control population consisted of 35 healthy individuals of different age and sex, who volunteered to 
provide blood samples at certain times through the study. WT1 expression values (normalized against 
GAPDH) from the 35 samples ranged from 0,002 to 0,109. We performed a chi-square goodness-of-fit 
test for normal distribution on control values (including a logarithmic transformation of data). According 
to the result, normality could be accepted (p=0,9923). We took the value at 97,5 percentile (0,108), and 
rounded it to 0,1 for easier use as a cut-off value for WT1-positivity in our study. 
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Results 
 
Diffuse large B-cell lymphoma 
 
Out of 53 patients, 25 were presented with DLBCL, so this group represents our largest sample. Median 
age at diagnosis was 54 years, ranging from 24 to 77 years. Treatment included CHOP and DHAP 
chemotherapy protocols combined with rituximab (monoclonal antibody against the CD20 antigen), and 
irradiation, autologous stem cell transplantation in certain cases. 
 
WT1-positivity was detected in 8 out of 25 cases, and Kaplan-Meier survival curves were drawn to study 
its effects on clinical outcome (Fig. 1). In overall survival, the WT1-positive subgroup produced a steeper 
curve – the observation was confirmed by a logrank test (p=0,0475). The difference in clinical outcome 
was even more striking when studying disease-free survival (p=0,0004). In 2 patients, we experienced an 
elevation over the cut-off value in a previously negative WT1 expression pattern. This seems to have been 
a sign of relapse: in one patient, WT1 expression was 0,002 during a partial remission, but increased to 
0,139 as measured in a sample taken on the day of her death due to a relapse, while in another case, a 
previously low expression value (0,0019) showed a massive peak of 226,0 during a relapse, 6 weeks 
preceding death. 
 
 
Fig. 1 Kaplan-Meier curves representing survival of DLBCL patients. Overall survival (A) and disease-
free survival (B) were studied in WT1-negative (Group 1) and WT1-positive (Group 2) patients. In 
diagram C, we illustrated the difference in overall survival between patients who were WT1-negative 
throughout the study (Group 1), patients who started out negative but became positive at some point 
(Group 2), and patients who presented only WT1-positive samples (Group 3) 
 
Mantle cell lymphoma 
 
We had 8 cases of MCL, with an age range of 38 to 74 years at diagnosis (median age was 60 years). 
Hyper-CVAD, CHOP, DHAP and BEAM (the latter followed by autologous stem cell transplantation) 
protocols were used for treatment, most often administered together with rituximab. WT1-positivity was 
detected in 4 cases. One of the patients (pretreated for MCL 5 years before) expressed a value of 0,0026 
when entering our study, but presented an unusually high level of expression (2,07) a year later. Since his 
bone marrow sample showed signs of MDS, and he died of MDS 18 months afterwards, it seemed 
reasonable to omit the case from the MCL statistics and report it separately. 
 
Overall and disease-free survival was compared in WT1-positive and negative subgroups among the 
remaining 7 patients (Fig. 2). Kaplan-Meier curves and the logrank test seem to suggest a longer overall 
(p=0,0082) and disease-free survival (p=0,0177) for WT1-negative patients. Changes in WT1 expression 
through the observation period may also be worth noting: a patient who showed a positive value of 0,288 
at diagnosis went negative (0,0018) after 4 months of hyper-CVAD treatment, and he survived more than 
2 years until the last follow-up. 
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Fig. 2 Overall (A) and disease-free (B) survival in 7 MCL patients. Group 1 contained 4 patients who 
were WT1-negative over the course of our study, and 1 patient who was positive at diagnosis, but 
decreased below the cut-off value through therapy. Group 2 contained 2 WT1-positive patients (one of 
them showed negative values in the beginning, but became positive during the observation period) 
 
Peripheral T-cell lymphoma 
 
We had a group of 9 patients presented with PTCL at a median age of 50 years (range: 32 to 67 years). 
Classic chemotherapy protocols (CHOP, DHAP, BEAM) were applied, sometimes in combination with 
alemtuzumab. Autologous stem cell transplantation was also used in cases where (at least) partial 
remission had been achieved. 
 
WT1 expression over the cut-off value for positivity (0,1) was detected in 4 cases. However, unlike B-cell 
lymphomas detailed above, survival curves in PTCL showed no difference between WT1-positive and 
negative subgroups (Fig. 3) – results of logrank tests were p=0,3198 for overall, and p=0,8084 for 
disease-free survival. 
 
 
Fig. 3 Kaplan-Meier survival curves in PTCL: group 1 consisted of WT1-negative, and group 2 of WT1-
positive cases. Overall survival is shown in diagram A, and disease-free survival in diagram B 
 
Adult acute lymphoblastic leukemia 
 
We examined a smaller group of 7 patients with B-cell ALL. Age at diagnosis ranged between 19 and 65 
years, with a median of 48 years. Treatment consisted of Hoelzer regimen
 
[17] with Glivec in cases where 
translocation t(9;22) was detected. 
 
WT1-positivity was detected in 5 cases, and its effect on survival was examined (Fig. 4). 3 cases that 
were included in overall survival analysis died within 7 weeks after diagnosis, and 2 of them were WT1-
negative, so Kaplan-Meier curves were unremarkable. On the other hand, disease-free survival could be 
studied in 4 patients who all presented elevated WT1 expression in their first sample at diagnosis. Two of 
them remained positive, and died in relapses 25 and 41 weeks after reaching a temporary remission, while 
2 became negative after induction treatment. Clinically, they have remained in remission since then. A 
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logrank test comparing Kaplan-Meier curves for disease-free survival is not far from being significant 
(p=0,0896), which may be worth noting, given the small sample size. 
 
 
Fig. 4 Effects of WT1 overexpression on survival in adult ALL patients: overall (A) and disease-free (B) 
survival. Group 1 contained 2 WT1-negative patients (they died 2 and 7 weeks after diagnosis, so disease-
free survival is not applicable). Group 2 consisted of 3 patients whose WT1 expression remained elevated 
through the course of our study, while group 3 had 2 patients who showed high WT1 expression at 
diagnosis that soon decreased into normal range during treatment 
 
MALT and Burkitt’s lymphoma 
 
We had 2 patients with MALT, and 2 with Burkitt’s lymphoma. All 4 cases proved to be WT1-negative.  
Remission was not achieved in either case of Burkitt’s lymphoma, and both patients died (after 18 and 38 
weeks, respectively). On the other hand, MALT lymphoma cases responded well to treatment, and both 
patients remain in remission after 203 and 136 weeks, respectively. 
 
Discussion 
 
The few studies available in the literature at present on the role of WT1 in lymphomas have all used 
immunohistochemical methods to detect the gene’s overexpression in tumor samples from various non-
Hodgkin lymphomas [15,18], and malignant lymph nodes from Hodgkin patients [19]. The latter study 
suggested WT1 as a possible proangiogenic factor in Hodgkin lymphoma. Wang et al. reported that 
detected levels of WT1 expression in anaplastic large-cell lymphoma (ALCL) did not have a significant 
impact on prognosis [18], but interpretation of their results is limited by the method of analyzing tumor 
samples taken at diagnosis, which only allows calculation of overall survival. Based on our own results 
and earlier studies on acute leukemias [11], we cannot exclude the possibility that the conclusion might 
have been different if they had determined disease-free survival as well. When planning our study, the 
first difficult decision was what type of sample and method to use. 
 
One could argue that samples from lymph nodes or tumor tissue are better to detect WT1 from, as they 
contain a much higher concentration of neoplastic cells than blood does. Our aim, however, was to obtain 
a relatively large number of samples over a certain time interval from each patient, and use qRT-PCR for 
fast analysis, in order to determine a correlation between the molecular and clinical state of the disease, 
and evaluate WT1 as a potential prognostic factor. One problem with neoplastic lymph node and tumor 
tissue samples is that they are no longer available after surgical removal. The other problem is that control 
samples are hard to come by, so it is not easy to decide what level of expression should be considered 
“WT1-positive”. Comparison to values in literature does not help, either, since procedures of collecting 
and storing samples as well as analyzing them in the laboratory can be so different that results are 
unlikely to be on the same scale. While measuring WT1 expression is not easy even by qRT-PCR, we 
believe that our method of using blood samples (with a fairly large pool of controls) and characterizing 
gene expression by numerical values (after normalization against GAPDH) has produced a reliable cut-off 
value that could be used as a threshold for WT1-positivity in our study. 
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In DLBCL, our results suggest that WT1 might be a useful marker to assess prognosis and monitor 
treatment, although our sample pool was not large, and included patients who were not available for 
sampling at the time of diagnosis. WT1-positivity seems to be present in about one-third of the cases: 6 
out of 18 cases in an earlier study [15], and 8 out of 25 in ours. This observation also implies that the 
detected frequency of WT1-positivity may not depend on the analyzed sample type (blood or lymph 
node). WT1-positive patients showed significantly worse overall and disease-free survival under the same 
treatment protocols. The difference in significance in favor of disease-free survival is to be expected: 
overall survival analysis included cases at various Ann Arbor stages at diagnosis, so short-term survival 
did not show much of a difference (Fig. 1A). 
 
To our knowledge, we document cases of WT1-positive MCL for the first time: Drakos et al. reported 6 
cases of MCL, none of which expressed WT1 [15]. We think that the difference in survival between 
WT1-positive and WT1-negative MCL patients is somewhat suggestive for a possible oncogenic role by 
WT1, although interpretation of the data is difficult due to the small sample size and the diverse range of 
chemotherapeutics used in different cases as required by international protocols in MCL. We experienced 
a substantial elevation in WT1 expression, and concurrent signs of MDS in the bone marrow in a patient 
pretreated for MCL. It is known in the literature that overexpression of WT1 may also be interpreted as an 
early sign of MDS [20]. In this light, the level of WT1 expression in lymphoma patients takes on a new 
significance as a marker for MDS or secondary AML in heavily pretreated patients. 
 
Finding both cases of Burkitt’s lymphoma to be WT1-negative was contrary to our previous expectations. 
However, evidence regarding the presence and significance of WT1 overexpression is somewhat 
controversial in the literature as well [15,21]. 
 
Our findings in B-cell ALL fit in with the results of recent large-scale studies [12-14],
 
including the 
observation that a sudden increase in WT1 expression seems to be associated with an increased risk of 
relapse. However, our results in ALL represent only a minor contribution to previous reports, since our 
sample size was relatively small. 
 
Although our own results in T-cell lymphoproliferative disorders are somewhat difficult to interpret, WT1 
is hypothesized to play a role in the pathogenesis of certain high-grade T-cell non-Hodgkin lymphomas 
[15]. Tosello et al. found WT1 mutations in 13.2% of pediatric and 11.7% of adult T-ALL, but according 
to survival analysis, cases with WT1 mutations did not have an adverse prognosis in either pediatric or 
adult T-ALL [22]. In a recent study, 20 of the 238 T-ALL patients analyzed had WT1 mutations in exon 7. 
WT1 mutations resulted in an inferior relapse-free survival in standard risk thymic T-ALL patients [23]. 
 
We can conclude that apart from its well-known role in acute leukemias, WT1 might also act as an 
oncogene in certain non-Hodgkin lymphomas. The least we should consider is that WT1 gene expression 
analysis might provide relevant information on disease progression in DLBCL, providing a tool for the 
more accurate assessment of remissions and relapses. We propose further investigation – a study should 
be conducted to evaluate survival in a larger group of DLBCL patients, applying a unified sampling 
strategy. Based on the results of future studies, WT1 might even become a therapeutic target in cases 
involving a relapse that resists conventional treatment, as it did in leukemias [24].
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